BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21215643)

  • 1. Microwave-assisted synthesis of quinoline, isoquinoline, quinoxaline and quinazoline derivatives as CB2 receptor agonists.
    Saari R; Törmä JC; Nevalainen T
    Bioorg Med Chem; 2011 Jan; 19(2):939-50. PubMed ID: 21215643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of quinolinyl and isoquinolinyl phenyl ketones as novel agonists for the cannabinoid CB2 receptor.
    Reux B; Nevalainen T; Raitio KH; Koskinen AM
    Bioorg Med Chem; 2009 Jul; 17(13):4441-7. PubMed ID: 19477133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
    Chu GH; Saeui CT; Worm K; Weaver DG; Goodman AJ; Broadrup RL; Cassel JA; DeHaven RN; LaBuda CJ; Koblish M; Brogdon B; Smith S; Le Bourdonnec B; Dolle RE
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5931-5. PubMed ID: 19736007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.
    Gomtsyan A; Bayburt EK; Schmidt RG; Zheng GZ; Perner RJ; Didomenico S; Koenig JR; Turner S; Jinkerson T; Drizin I; Hannick SM; Macri BS; McDonald HA; Honore P; Wismer CT; Marsh KC; Wetter J; Stewart KD; Oie T; Jarvis MF; Surowy CS; Faltynek CR; Lee CH
    J Med Chem; 2005 Feb; 48(3):744-52. PubMed ID: 15689158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.
    Manley PJ; Zartman A; Paone DV; Burgey CS; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT; Trotter BW
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2359-64. PubMed ID: 21420857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.
    Manera C; Cascio MG; Benetti V; Allarà M; Tuccinardi T; Martinelli A; Saccomanni G; Vivoli E; Ghelardini C; Di Marzo V; Ferrarini PL
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6505-10. PubMed ID: 17942307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
    Manera C; Benetti V; Castelli MP; Cavallini T; Lazzarotti S; Pibiri F; Saccomanni G; Tuccinardi T; Vannacci A; Martinelli A; Ferrarini PL
    J Med Chem; 2006 Oct; 49(20):5947-57. PubMed ID: 17004710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Sulfonyl-benzimidazoles as selective CB2 agonists.
    Verbist BM; De Cleyn MA; Surkyn M; Fraiponts E; Aerssens J; Nijsen MJ; Gijsen HJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2574-9. PubMed ID: 18394887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as selective CB(2) cannabinoid receptor ligands: structural investigations around a novel class of full agonists.
    Baraldi PG; Saponaro G; Moorman AR; Romagnoli R; Preti D; Baraldi S; Ruggiero E; Varani K; Targa M; Vincenzi F; Borea PA; Aghazadeh Tabrizi M
    J Med Chem; 2012 Jul; 55(14):6608-23. PubMed ID: 22738271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
    De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
    J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor.
    Salo OM; Raitio KH; Savinainen JR; Nevalainen T; Lahtela-Kakkonen M; Laitinen JT; Järvinen T; Poso A
    J Med Chem; 2005 Nov; 48(23):7166-71. PubMed ID: 16279774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
    Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
    J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of 2,4,6-trisubstituted 1,3,5-triazines as CB2 agonists.
    Yrjölä S; Kalliokoski T; Laitinen T; Poso A; Parkkari T; Nevalainen T
    Eur J Pharm Sci; 2013 Jan; 48(1-2):9-20. PubMed ID: 23131798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel class of adenosine A3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds.
    van Muijlwijk-Koezen JE; Timmerman H; Link R; van der Goot H; Ijzerman AP
    J Med Chem; 1998 Oct; 41(21):3994-4000. PubMed ID: 9767637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors.
    Govaerts SJ; Muccioli GG; Hermans E; Lambert DM
    Eur J Pharmacol; 2004 Jul; 495(1):43-53. PubMed ID: 15219819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists.
    Muccioli GG; Wouters J; Scriba GK; Poppitz W; Poupaert JH; Lambert DM
    J Med Chem; 2005 Nov; 48(23):7486-90. PubMed ID: 16279809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
    Diaz P; Phatak SS; Xu J; Astruc-Diaz F; Cavasotto CN; Naguib M
    J Med Chem; 2009 Jan; 52(2):433-44. PubMed ID: 19115816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.
    Ermann M; Riether D; Walker ER; Mushi IF; Jenkins JE; Noya-Marino B; Brewer ML; Taylor MG; Amouzegh P; East SP; Dymock BW; Gemkow MJ; Kahrs AF; Ebneth A; Löbbe S; O'Shea K; Shih DT; Thomson D
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1725-9. PubMed ID: 18255291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.
    Trotter BW; Nanda KK; Burgey CS; Potteiger CM; Deng JZ; Green AI; Hartnett JC; Kett NR; Wu Z; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2354-8. PubMed ID: 21420860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.
    Pasquini S; De Rosa M; Ligresti A; Mugnaini C; Brizzi A; Caradonna NP; Cascio MG; Bolognini D; Pertwee RG; Di Marzo V; Corelli F
    Eur J Med Chem; 2012 Dec; 58():30-43. PubMed ID: 23085772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.